A multicenter, prospective, randomized, open-label, parallel-group, phase 4 clinical trial comparing the efficacy and safety of adding a thiazolidinedione or a dipeptidyl peptidase-4 inhibitor as a third-line therapy in patients with type 2 diabetes mellitus inadequately controlled with metformin and a sodium-glucose co-transporter 2 inhibitor dual therapy.

Authors
Category Primary study
Registry of TrialsKorean Clinical Trials Database
Year 2025
This article has no abstract
Epistemonikos ID: a32d031ecb091738c5208913316f12a5330596d2
First added on: Apr 11, 2025